NCT05766709View on ClinicalTrials.gov

A Research Study Comparing Blood Levels of Medicines NNC0194-0499 and Semaglutide Administered as a Combination Formulation Versus Two Separate Formulations

PHASE1CompletedINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

March 2, 2023

Primary Completion Date

January 5, 2024

Study Completion Date

February 9, 2024

Conditions
Non-alcoholic Steatohepatitis
Interventions
DRUG

NNC0194-0499

NNC0194-0499 will be administered subcutaneously once weekly.

DRUG

Semaglutide

Semaglutide will be administered subcutaneously once weekly.

DRUG

NNC0194-0499/Semaglutide A (40/3.20 mg/mL)

NNC0194-0499/Semaglutide A (40/3.20 mg/mL) co-formulation product will be administered subcutaneously once weekly.

DRUG

NNC0194-0499/Semaglutide A (40/0.33mg/mL)

NNC0194-0499/Semaglutide A (40/0.33mg/mL) will be administered subcutaneously once weekly.

Trial Locations (1)

H3P 3P1

Altasciences Company Inc., Montreal

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY

NCT05766709 - A Research Study Comparing Blood Levels of Medicines NNC0194-0499 and Semaglutide Administered as a Combination Formulation Versus Two Separate Formulations | Biotech Hunter | Biotech Hunter